Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. (2022)
Attributed to:
'SPIICA' - the Sao Paulo-Imperial College Immune Correlates in Arbovirus Infection Network
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41467-022-28517-z
PubMed Identifier: 35296643
Publication URI: http://europepmc.org/abstract/MED/35296643
Type: Journal Article/Review
Volume: 13
Parent Publication: Nature communications
Issue: 1
ISSN: 2041-1723